Shattuck Labs (STTK)

Its lead program is SL-325, an antibody designed to antagonize death receptor 3, or DR3. DR3 is part of the tumor necrosis factor receptor superfamily and is associated with immune signaling pathways that may contribute to chronic inflammation. By blocking this target, Shattuck aims to create a therapeutic approach that could be differentiated from existing treatments used in diseases such as ulcerative colitis and Crohn’s disease. The company describes SL-325 as a potentially first-in-class DR3 antagonist antibody.

Shattuck is also developing SL-425, a half-life-extended version of SL-325, along with additional preclinical DR3-based bispecific antibodies. These programs reflect the company’s broader strategy of building a pipeline around engineered biologics that can modulate immune pathways with precision. Its research platform and drug candidates are still subject to the clinical development process, where safety, efficacy, dosing, and durability must be demonstrated through trials.

As a public biotechnology stock, Shattuck Labs is primarily evaluated on the progress of its pipeline, clinical data, regulatory milestones, cash position, and the competitive landscape in immunology. The company’s distinctive focus is its work on DR3 biology and the potential to develop new treatment options for patients with inflammatory bowel disease and other immune-driven disorders.